Zealand Pharma company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

zealandpharma.com

Executives

16

Zealand Pharma Management Team

16 Team Members

Zealand Pharma has 16 executives. Zealand Pharma's current Chief Executive Officer, President is Adam Steensberg.

Name

Work History

Title

Status

Adam Steensberg

Novo Nordisk, Righospitalet, and Amag

Chief Executive Officer, President

Current

John Hyttel

Senior Vice President

Current

Britt Meelby Jensen

Chief Executive Officer, President

Former

David Horn Solomon

Chief Executive Officer, President

Former

Eva Steiness

Chief Executive Officer

Former

Name

Adam Steensberg

John Hyttel

Britt Meelby Jensen

David Horn Solomon

Eva Steiness

Work History

Novo Nordisk, Righospitalet, and Amag

Title

Chief Executive Officer, President

Senior Vice President

Chief Executive Officer, President

Chief Executive Officer, President

Chief Executive Officer

Status

Current

Current

Former

Former

Former

You May Also Like

M
Metronome Therapeutics

Metronome Therapeutics is developing oncology drugs

E
Ethos Pharmaceuticals

Developer of novel variants of peptide drugs.

X
Xytis

Xytis is engaged in the development of central nervous systems drugs.

O
OyaGen

OyaGen is a biotechnology company discovering, developing, and commercializing pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. The company will pursue several assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states.

K
KeyBay Pharma

KeyBay Pharma is dedicated to the discovery, development and commercialization of antibiotics.

E
Endotis Pharma

Endotis Pharma is A specialty discovery and development company developing small glycol drugs for thrombosis and oncology

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.